Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.59 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23879203 | 0.87 | LOXL2 (0.71) | LOXL2CYP2A6SCN8ACYP19A1CACNA1G | |
| SCHEMBL15831741 | 0.84 | LOXL2 (0.62) | LOXL2CYP2A6SCN8ACYP19A1CACNA1G | |
| SCHEMBL29912750 | 0.83 | LOXL2 (0.65) | LOXL2CYP2A6SCN8ACYP19A1CACNA1G | |
| SCHEMBL9180552 | 0.82 | LMNA (0.52) | ALDH1A1KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2828109 | 0.81 | SCN8A (0.58) | LOXL2CYP2A6SCN8ACYP19A1CACNA1G | |
| SCHEMBL509578 | 0.80 | LOXL2 (1.00) | LOXL2CYP2A6SCN8ACYP19A1CACNA1G | |
| SCHEMBL26148107 | 0.80 | CYP2A6 (0.55) | LOXL2CYP2A6SCN8ACYP19A1CA12 | |
| SCHEMBL8897410 | 0.79 | LOXL2 (0.61) | LOXL2CYP2A6SCN8ACYP19A1CACNA1G | |
| SCHEMBL6353289 | 0.79 | LOXL2 (0.61) | LOXL2CYP2A6SCN8ACYP19A1CACNA1G | |
| SCHEMBL7050164 | 0.79 | LOXL2 (0.61) | LOXL2CYP2A6SCN8ACYP19A1CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250338848-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12441704-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| US-20240284908-A1 | Fungicidal Compositions | SYNGENTA PARTICIPATIONS AG (CH) | 2024-08-29 | — | — | US | disclosed |
| US-11974572-B2 | Fungicidal compositions | SYGENTA PARTICIPATIONS AG (CH) | 2024-05-07 | — | — | US | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-11780843-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-10-10 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| US-11685727-B2 | Compounds active towards nuclear receptors | NUEVOLUTION A/S (DK) | 2023-06-27 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| CN-1332942-C | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-22 | — | — | CN | disclosed |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-19 | — | — | US | disclosed |
| CN-1703397-A | Sulfonylamino-acetic acid derivatives and their use as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2005-11-30 | — | — | CN | disclosed |
| EP-1554239-A2 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | BOHM HANS-JOACHIM (DE) | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240284908-A1 | Fungicidal Compositions | CYP51A1, CYP4X1, CYP1B1 | LOXL2 1993/4885CYP2A6 139/4885SCN8A 3774/4885 |
| US-20250338848-A1 | FUNGICIDAL COMPOSITIONS | CYP3A7, DHCR7, CASP7 | LOXL2 4404/4885CYP2A6 18/4885SCN8A 630/4885 |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | HCRTR2, HCRTR1, GIPR | LOXL2 4004/4885CYP2A6 1084/4885SCN8A 1322/4885 |
| US-11780843-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | LOXL2 3242/4885CYP2A6 559/4885SCN8A 2603/4885 |
| US-11685727-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | LOXL2 3242/4885CYP2A6 559/4885SCN8A 2603/4885 |
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | LOXL2 3242/4885CYP2A6 559/4885SCN8A 2603/4885 |
| US-11974572-B2 | Fungicidal compositions | CYP51A1, CYP4X1, CYP1B1 | LOXL2 1993/4885CYP2A6 139/4885SCN8A 3774/4885 |
| US-12441704-B2 | Compounds active towards nuclear receptors | NCOA1, NR1H2, NCOA3 | LOXL2 3242/4885CYP2A6 559/4885SCN8A 2603/4885 |
| US-20030004308-A1 | Novel thrombin inhibitors, the preparation and use thereof | TFPI, SERPINC1, F2 | LOXL2 2231/4885CYP2A6 706/4885SCN8A 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.